Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 70 Squamous Cell Carcinoma of Head and Neck 32 Parkinson Disease 4, Autosomal Dominant Lewy Body 30 Lung Neoplasms 28 Melanoma 24 Triple Negative Breast Neoplasms 23 Neoplasms 20 Neoplasm Metastasis 20 Breast Neoplasms 19 Colorectal Neoplasms 18 Head and Neck Neoplasms 15 Endometrial Neoplasms 15 Ovarian Neoplasms 14 Carcinoma, Renal Cell 13 Urinary Bladder Neoplasms 11 Carcinoma, Transitional Cell 10 Pancreatic Neoplasms 7 Hodgkin Disease 7 Esophageal Neoplasms 7 Uterine Cervical Neoplasms 6 Sarcoma 6 Recurrence 6 Lymphoma 6 Carcinoma 6 Stomach Neoplasms 4 Small Cell Lung Carcinoma 4 Prostatic Neoplasms 4 Multiple Myeloma 4 Mouth Neoplasms 4 Lymphoma, Large B-Cell, Diffuse 4

Interventions

Cisplatin 12 Gemcitabine 9 Specimen Handling 6 Radiotherapy, Intensity-Modulated 6 Magnetic Resonance Spectroscopy 6 Drug Therapy 5 toripalimab 4 Platinum 4 Nivolumab 4 Capecitabine 4 1,2-diaminocyclohexaneplatinum II citrate 4 spartalizumab 3 Radiotherapy 3 Immune Checkpoint Inhibitors 3 sintilimab 2 Ipilimumab 2 Immunoglobulin G 2 Docetaxel 2 Disulfides 2 Carboplatin 2 CTLA-4 Antigen 2 Biopsy 2 tislelizumab 1 relatlimab 1 pembrolizumab 1 olaparib 1 fluciclovine F-18 1 dehydroftorafur 1 cemiplimab 1 camrelizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Nasopharyngeal Carcinoma × pembrolizumab × 30 days × Clear all

NCT04825990 2026-06-01

POINT

Gruppo Oncologico del Nord-Ovest

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡